Table 1.
Cohort description
| Characteristic | Total, N=78 (%) |
|---|---|
| Median age at transplant, years (range) | 53 (23-69) |
| Median time from diagnosis to transplant, months (range) | 12 (7-81) |
| Gender -Male -Female |
50 (64) 28 (36) |
| International Staging System -I -II -III -Missing |
27 (35) 21 (27) 28 (36) 2 (2) |
| IMWG Risk Status -Standard risk -Intermediate Risk -High Risk -Missing |
22 (28) 29 (37) 13 (17) 14 (18) |
| Disease Status at Transplant -sCR, CR or VGPR -PR -Stable or Progressive disease |
25 (32) 48 (62) 5 (6) |
| Donor type -Related* -Unrelated |
70 (90) 8 (10) |
| Type of transplant -Myeloablative -Non-myeloablative |
11 (14) 67 (86) |
| Conditioning regimen -Low dose TBI +/− others -Cyclophosphamide/Fludarabine -Cyclophosphamide/TBI -Fludarabine/Melphalan -Fludarabine/TBI -Others# |
46 (59) 7 (9) 4 (5) 11 (14) 6 (8) 4 (5) |
| Median CD34 cells infused, × 106 cells/kg (range) | 7.3 (1.1-32.5) |
| Acute GVHD -None -Grade 1 -Grade 2 -Grade 3 -Grade 4 -Missing |
41 (53) 14 (18) 14 (18) 5 (6) 3 (4) 1 (1) |
| Chronic GVHD -Present -Absent |
29 (37) 49 (63) |
| CMV reactivation | 14 (18) |
| Received DLI infusion | 9 (12) |
| Relapse/progression of myeloma | 27 (35) |
| Cause of death (N=34) -Disease -Transplant related mortality |
14 (41) 20 (59) |
| Baseline ALC ≥500 × 106 cells/L | 62 (80) |
| Baseline AMC ≥300 × 106 cells/L | 54 (69) |
| Day 100 ALC ≥500 × 106 cells/L | 48 (62) |
| Day 100 AMC ≥300 × 106 cells/L | 45 (58) |
| Median follow up of surviving patients, months (range) | 49.4 (2.3 – 129.3) |
*
Related- 1-syngeneic, 1-haploidentical
#
Others- Mel- 1, FUMEP- 2, Flu-Bu- 1
IMWG- International Myeloma Working Group, sCR- stringent complete response, CR- somplete response, VGPR- very good partial response, PR- partial response, CMV- cytomegalovirus, DLI- donor lymphocyte infusion